INKT News and Press, MiNK Therapeutics Inc. From 03/25/23

2023-03-25 02:17:53 ET Summary AgenT-797 data presented at SITC in November was encouraging. More AgenT-797 cancer data expected at AACR on April 18. But cash is low, so will need to raise more to continue operations. MiNK Therapeutics ( INKT ) was formed in 2021...

2023-03-21 12:26:01 ET MiNK Therapeutics, Inc. (INKT) Q4 2022 Results Conference Call March 21, 2023 08:30 AM ET Company Participants Zack Armen - Head of Investor Relations at MiNK Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Princi...

2023-03-21 08:59:27 ET MiNK Therapeutics press release ( NASDAQ: INKT ): Q4 GAAP EPS of $0.23. cash balance of $19.6 million Cash used in operations for the year and fourth quarter ended December 31, 2022, was $18.9 million, and $4.4 million For further details s...

Clinical update of allo-iNKTs (agenT-797) in solid tumors to be presented at AACR Annual Meeting in April 2023 AgenT-797 in combination with pembro or nivo in NSCLC and gastric cancer to initiate in 2023 Allogeneic CAR platform demonstrates differentiation with IL-15-FAP-CAR-iNKT (MiNK-...

– Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, developmen...

NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other imm...

NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated dis...

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediate...

NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-me...

Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively, had a reduction of target and non-target lesions or disease stabilization First immune cell...